NDAORALTABLET
Approved
Mar 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
5/8 — Partial
PONVORY (ponesimod) by Vanda Pharmaceuticals is sphingosine 1-phosphate receptor modulators [moa]. First approved in 2021.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PONVORY (ponesimod) is an oral sphingosine 1-phosphate receptor modulator approved in March 2021 for relapsing forms of multiple sclerosis. It modulates S1P receptors to reduce lymphocyte egress from lymphoid tissues, decreasing central nervous system infiltration. The drug represents a next-generation S1P modulator with improved selectivity and tolerability.
$8MPart D
Peak18.1 years to LOEProduct is at peak commercial stage with modest Part D utilization (~$8M in 2023), suggesting strong market presence but potential plateau in the competitive MS oral segment.
Mechanism of Action
Sphingosine 1-Phosphate Receptor Modulators
Pharmacologic Class:
Sphingosine 1-phosphate Receptor Modulator
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
Started Sep 2026
150 enrolled
Ulcerative Colitis (UC)
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Started Feb 2026
300 enrolled
Moderate-to-severe Chronic Plaque Psoriasis
A Study of Ponesimod in Healthy Adult Participants
Started Oct 2022
28 enrolled
Healthy
A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State
Started Mar 2019
52 enrolled
Healthy
Worked on PONVORY at Vanda Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.